You're signed outSign in or to get full access.
Tri Locum Partners LP
Tri Locum Partners LP is a New York-based, SEC-registered hedge fund founded in 2019 by Dr. Prashanth Jayaram, a former portfolio manager at Citadel. The firm specializes in healthcare investment, targeting both public and private opportunities globally. It offers discretionary investment management to qualified clients through private investment vehicles, and currently manages approximately $753 million in assets. As of April 2025, the firm employs 8 staff, primarily serving institutional investors in the financial services sector.
Investment Strategy
Tri Locum Partners deploys a market-neutral long/short equity strategy focused exclusively on healthcare sectors such as biotechnology, pharmaceuticals, medical devices, and services. Their approach blends deep fundamental, science-based research with proprietary portfolio construction and risk management techniques. This aims to generate superior idiosyncratic returns, with high concentration and minimized exposure to macroeconomic and market risks, targeting consistent risk-adjusted performance in all cycles.
Latest 13F Filing Activity
Tri Locum Partners LP filed their most recent 13F report on Jun 30, 2025 disclosing 23 equity positions with a total 13F market value of $330M. The fund increased holdings in Alnylam Pharmaceuticals Inc., Verona Pharma PLC, Ascendis Pharma A/s among other positions. Tri Locum Partners LP reduced exposure to Gilead Sciences Inc., Illumina Inc., Insmed Inc. among others.
Top Holdings
Equity Positions (23)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
T TEVA | TEVA PHARMACEUTICAL INDS LTD | 10.41% | $34.3M | 2,046,846 | $14.13 | $16.76 | +$18.0M |
M MDGL | MADRIGAL PHARMACEUTICALS INC | 8.98% | $29.6M | 97,765 | $285.05 | $302.64 | +$17.0M |
A ALNY | ALNYLAM PHARMACEUTICALS INC | 8.86% | $29.2M | 89,525 | $326.09 | $326.09 | +$29.2M |
A ARGX | ARGENX SE | 8.00% | $26.3M | 47,793 | $508.31 | $551.22 | +$15.8M |
A ASND | ASCENDIS PHARMA A/S | 7.73% | $25.5M | 147,642 | $168.93 | $172.60 | +$20.4M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more